Navigation Links
For Treatment of Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia, 41 Percent of Surveyed European Hematologist-Oncologists Say MabThera's Favorable Efficacy Profile is the Most Significant Driver of Their Use of This Agent
Date:8/30/2010

BURLINGTON, Mass., Aug. 30 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, 41 percent of surveyed European hematologist-oncologists say that the favorable efficacy profile of Roche's MabThera (rituximab) is the most significant driver of their use of this brand, while 26 percent say MabThera's favorable risk-benefit profile is the most significant driver.

The new European Physician & Payer Forum report entitled Will Emerging MAbs Threaten MabThera's Domination of the Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia Markets in Europe? Clinician and Payer Perspectives finds that sales of MabThera, which was first marketed more than a decade ago, continue to dwarf those of more recently launched monoclonal antibodies (MAbs) such as Genzyme's MabCampath and Bayer's Zevalin. When asked what safety/toxicity improvements over MabThera would carry the most weight in convincing prescribers to switch from MabThera to a novel MAb, the largest group of surveyed clinicians in France, Germany, Italy, Spain and the United Kingdom (EU5) cite concern about the rate of infections, although many are satisfied with the safety of MabThera.

"Thirty seven percent of surveyed European hematologist-oncologists say that an improvement in the rate of infections would carry the most weight, while 20 percent of surveyed clinicians cite concern about the rate of neutropenia," said Decision Resources Analyst Andrew Merron, Ph.D. "However, more than one-quarter of surveyed European hematologist-oncologists say that all side effects associated with MabThera are manageable."

The report also finds that emerging MAbs will not only face competition from MabThera in the EU5 markets but also from biosimilar rituximab. In the United Kingdom, interviewed payers expect that biosimilars will be
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
5. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Many Heart Attack Patients Dont Get Best Emergency Treatment
11. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... , Sept. 4, 2015  PTC Therapeutics, ... announce five recipients of its first-ever global awards ... Vision and Empowerment), designed to aid nonprofit organizations ... dystrophy (DMD) community. The announcement is made as ... World Duchenne Awareness Day on Monday, September 7, ...
(Date:9/4/2015)... , September 4, 2015 ... ), a clinical-stage pharmaceutical company focused on the development ... Company will participate in the upcoming Rodman & Renshaw ... September 8-10, 2015 in New York City ... Oramed, will present a corporate overview on September 9, ...
(Date:9/4/2015)... , September 4, 2015 Future ... Allergic Rhinitis drugs - new ... Where is the market for allergic rhinitis drugs ... Visiongain ,s new report shows you potential revenues ... prospects. Our 326 page report provides 273 ...
Breaking Medicine Technology:PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 2PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 3PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 4Oramed to Present at the Rodman & Renshaw Global Investment Conference 2Oramed to Present at the Rodman & Renshaw Global Investment Conference 3Allergic Rhinitis Drugs Market Forecast 2015-2025 2Allergic Rhinitis Drugs Market Forecast 2015-2025 3Allergic Rhinitis Drugs Market Forecast 2015-2025 4Allergic Rhinitis Drugs Market Forecast 2015-2025 5Allergic Rhinitis Drugs Market Forecast 2015-2025 6Allergic Rhinitis Drugs Market Forecast 2015-2025 7
... Globus Medical, Inc., the largest,privately held spinal ... in motion preservation technology, today announced the completion ... study. The,SECURE(R)-C device is designed to mimic the ... pain and restore function as an alternative to ...
... Siemens Healthcare and,Laboratory Corporation of America(R) Holdings ... non-exclusive agreement to discuss future,possibilities to co-develop ... of,companion diagnostics, metabolic syndrome, oncology and diabetes. ... developing new tests that,could make the biggest ...
Cached Medicine Technology:Globus Medical Completes Enrollment Of SECURE(R)-C Cervical Artificial Disc Clinical Trial 2Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 2Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 3Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 4
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... ... 2014, Insight Product Development has effectively doubled the size of its annual health ... Midwest medical device and digital health startups to compete for cash and prizes ...
(Date:9/4/2015)... ... 04, 2015 , ... Mile High Connects today releases “First and Last Mile ... for sidewalks, bike paths, and other vital supports severely limit access to public transportation ... of dollars to expand public transit, there’s very little support for safe and convenient ...
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... The Providence ... to learn more about their fertility and egg freezing. , Date and Time: October ... 6PM to 7PM , This hip and informative event will discuss the basics of ...
(Date:9/4/2015)... ... 2015 , ... Georgia Insurance Advisors, a locally owned insurance ... provide for the family of Grace, a young local girl battling restrictive cardiomyopathy. ... to diastolic dysfunction – the inability to adequately move blood through the circulatory ...
(Date:9/4/2015)... ... September 04, 2015 , ... Inmar announced today ... meeting of its Product, Quality and Manufacturers, Dietary Supplements and Supply Chain Committees. ... in the consumer goods industry, it can be difficult for companies to navigate, ...
Breaking Medicine News(10 mins):Health News:Insight Product Development Startup Competition on Track to Double Program Impact 2Health News:Insight Product Development Startup Competition on Track to Double Program Impact 3Health News:Missed Connections in Metro Denver Transit 2Health News:The Providence Fertility Center to Host Fertility Cocktail Hour on October 8, 2015 at Waterman Grille for Women Who Wish to Learn About Their Fertility and Egg Freezing 2Health News:Georgia Insurance Advisors Inaugurates Charity Drive to Assist the Family of Young Local Girl Diagnosed with an Enlarged Heart 2Health News:Georgia Insurance Advisors Inaugurates Charity Drive to Assist the Family of Young Local Girl Diagnosed with an Enlarged Heart 3Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 2Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 3
... The Disabled American,Veterans (DAV) is commending lawmakers ... largest increase in funding for the Department of,Veterans ... Congress and the,Administration to support this important legislation ... Construction and Veterans Affairs Appropriations bill,calls for an ...
... The Netherlands, Nov. 6 Kiadis Pharma,announced today ... orphan drug,designation by the US Food and Drug ... prevention of Graft versus Host Disease (GvHD),following allogeneic ... clinical studies and anticipated to enter clinical phase ...
... Nov. 6 The American Public,Health Association today ... health issues from food safety and obesity to ... are descriptions of some of the various measures ... Annual Meeting in,Washington, D.C., Nov. 3-7. Full policies ...
... further underperformance and ... deterioration of shareholder value., ANAHEIM, Calif., ... health benefit and pension fund trustees and,administrators are in ... Plans conference. The conference is,considered a premier marketing opportunity ...
... Canadian researchers expect to accelerate the war on cancer by ... people who volunteer their idle computer time to tackle some ... team, led by Dr. Igor Jurisica at the Ontario Cancer ... Health Network, are the first from Canada to use the ...
... hepatitis C and advanced liver disease who did ... decreases in their liver enzymes, viral levels, and ... However, the treatment did not slow or prevent ... come from the clinical trial, Hepatitis C Antiviral ...
Cached Medicine News:Health News:VA Budget Earns High Praise 2Health News:FDA Grants Kiadis Pharma Lead Product ATIR Orphan Drug Designation 2Health News:FDA Grants Kiadis Pharma Lead Product ATIR Orphan Drug Designation 3Health News:APHA Adopts New Policies on Food Safety, Global Climate Change, Multidrug-Resistant Organisms, Breastfeeding and Feminine Hygiene 2Health News:APHA Adopts New Policies on Food Safety, Global Climate Change, Multidrug-Resistant Organisms, Breastfeeding and Feminine Hygiene 3Health News:APHA Adopts New Policies on Food Safety, Global Climate Change, Multidrug-Resistant Organisms, Breastfeeding and Feminine Hygiene 4Health News:Labor Union Coalition Alerts Industry Analysts About Rite Aid 2Health News:Labor Union Coalition Alerts Industry Analysts About Rite Aid 3Health News:IBM world community grid squeezes decades of cancer research into 2 years 2Health News:Hepatitis C treatment reduces the virus but serious liver problems may progress 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: